Company Description

Sanzyme Biologics® (founded as Uni-Sankyo in the year 1969) is a pioneer in probiotics. Today, it has a market presence in over 40 countries across the globe, including the US, Canada, Europe, Japan, South Korea, Australia, New Zealand, India, China, and Taiwan. Sanzyme Biologics manufactures aerobic spore formers (Bacillus coagulans SNZ 1969®, Bacillus clausii SNZ 1971™, and Bacillus subtilis SNZ 1972™), aerobic vegetative strains (lactobacillus spp. etc.) and yeast (Saccharomyces boulardii SNZ 1986™) in its world class NSF certified facility at Hyderabad, India. It adopts proprietary technology and has a sound selection of strains meeting global standards. Flagship strain Bacillus coagulans SNZ 1969® spores are robust and offers flexibility to food, supplement, and pharma product formulators. It sustains processing conditions, gut pH, bile salt and does not require cold chain unlike vegetative probiotic strains. It has US FDA GRAS (including infants), Health Canada approval, non-GMO project verified and supported with 30 plus scientific publications around gut health, oral health, and women’s health. SNZ 1969® could be incorporated in a wide variety of food and beverage formats such as cereal bars, protein bars, meal replacers, breakfast cereals, tea, coffee, kombucha, cookies, seasonings, nuts, chocolates, lozenges, mint tablets, gummies, hard boiled candies, health food drinks (health beverages)s, fat spreads etc.

Brands: Bacillus coagulans SNZ 1969, Bacillus clausii SNZ 1971, Bacillus subtilis SNZ 1972, Saccharomyces boulardii SNZ 1986, TriBac SNZ

 Press Releases

• SNZ 1969® helps manage IBS-D & IBS-C symptoms effectively, demonstrates the latest clinical study (Oct 26, 2022)

  Bacillus coagulans SNZ 1969®, a natural spore forming probiotic strain with five decades history of use and over 30 human studies across age groups found to be effective in managing IBS symptoms, demonstrates the latest clinical study.  This study is unique as it covers both the IBS-D and IBS-C groups with larger number of subjects.

  Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction, estimated to affect around 11% people globally.  The outcome of this study will be significant to supplement manufacturers as it can help design products to address consumer need for managing IBS symptoms with a scientifically studied probiotic strain.

  In a randomized, double blind, placebo-controlled study¹, probiotic potential (efficacy and safety) of SNZ 1969® has been studied in patients with constipation predominant irritable bowel syndrome (IBS-C) and diarrhea predominant irritable bowel syndrome (IBS-D).  Reduction in the GSRS-IBS score was greater in the treatment group (39.78%) compared to the placebo group (2.42%). Consistent reductions in the GSRS-IBS score also seen in patients with IBS-D from baseline (62.5±3.9) to day 75 (34.45±3.53) (p<0.0001) after treatment with SNZ 1969®.  The study showed most patients (90%) with IBS-C and 100% with IBS-D responded to SNZ 1969® as compared to no responders treated with placebo, p<0.0001.  SNZ 1969® was found to be safe and effective alternative to therapeutic option for IBS patients as it alleviates IBS-associated clinical symptoms and improves the quality of life as compared to placebo.

  This study was conduct at Apollo Hospitals, Hyderabad, India and published in the International Journal of Basic & Clinical Pharmacology.  https://www.ijbcp.com/index.php/ijbcp/article/view/5120

  The same strain has been studied earlier for gastrointestinal discomfort, intestinal motility and intermittent constipation among health subjects.  GI discomfort study² showed an improvement in total SODA scores, including specific symptoms such as burping/belching, bloating, heartburn, passing gas, nausea, bad breath, and sour taste compared with placebo.  Intestinal motility³ study concluded that SNZ 1969® reaches the colon intact and ameliorates intestinal motility and gut microbiota composition by enhancing lactobacillales and diminishing synergistales.  With the latest IBS study, the overall digestive health positioning of SNZ 1969® has been bolstered and made SNZ 1969® an ultimate option for food and supplement manufacturers around the globe.

  About Sanzyme Biologics

  Sanzyme Biologics was incorporated in 1969 as Uni-Sankyo and was the first company to manufacture and sell probiotics in the Indian market.  Over the last five decades Sanzyme Biologics established its strength in probiotics by developing scientifically studied and well-documented probiotic strains, pioneered their applications beyond human health into aqua, veterinary, poultry and bioremediation.  Sanzyme Biologics has market presence in over 40 countries across the globe. 

  References:

  1. Evaluation of efficacy and safety of Bacillus coagulans SNZ 1969 supplementation for irritable bowel syndrome: a randomized, double-blind, placebo-controlled study.  International Journal of Basic & Clinical Pharmacology Soman RJ et al. Int J Basic Clin Pharmacol. 2022 Nov;11(6):xxx-xxx (In Press)
  2. Efficacy and Safety of Probiotic Bacillus coagulans SNZ 1969 in Gastrointestinal Discomfort: A Randomized, Placebo-Controlled Study.  Soman RJ et al.  International Journal of Health Sciences and Research  Vol.12; Issue: 3; March 2022
  3. Spore-forming Bacillus coagulans SNZ 1969 improved intestinal motility and constipation perception mediated by microbial alterations in healthy adults with mild intermittent constipation: A randomized controlled trial.  Seunghee Kang et al.  Food Research International Volume 146, August 2021, 110428

 Additional Info

Categories